Social and structural determinants of injection drug use-associated bacterial and fungal infections: a qualitative systematic review and thematic synthesis

4 5

Running title: Determinants of injecting-related infections

6 7

Thomas D. Brothers^{1,2}, Matthew Bonn³, Dan Lewer¹, Emilie Comeau⁴, Inhwa Kim⁴, Duncan Webster^{2,5},
 Andrew Hayward¹, Magdalena Harris⁶

10

¹UCL Collaborative Centre for Inclusion Health, Institute of Epidemiology and Health Care, University

- 12 College London, London, UK
- 13 ²Department of Medicine, Faculty of Medicine, Dalhousie University, Halifax, Canada
- 14 ³Canadian Association of People who Use Drugs (CAPUD), Dartmouth, Canada
- 15 ⁴Faculty of Medicine, Dalhousie University, Halifax, Canada
- 16 ⁵Division of Infectious Diseases, Saint John Regional Hospital, Saint John, Canada
- ⁶Department of Public Health, Environments and Society, London School of Hygiene & Tropical
- 18 Medicine, London, UK
- 19
- 20

21 Address correspondence to: thomas.brothers.20@ucl.ac.uk; thomas.brothers@dal.ca (TDB)

23 ABSTRACT

24	Background: Injection drug use-associated bacterial and fungal infections are increasingly common, and
25	social contexts shape individuals' injecting practices and treatment experiences. We sought to
26	synthesize qualitative studies of social-structural factors influencing incidence and treatment of
27	injecting-related infections.
28	Methods: We searched PubMed, EMBASE, Scopus, CINAHL, and PsycINFO from January 1, 2000, to
29	February 18, 2021. Informed by Rhodes' "risk environment" framework, we performed thematic
30	synthesis in three stages: (1) line-by-line coding; (2) organizing codes into descriptive themes, reflecting
31	interpretations of study authors; (3) consolidating descriptive themes into conceptual categories to
32	identify higher-order analytic themes.
33	Results: We screened 4,841 abstracts and included 26 qualitative studies on experiences of injecting-
34	related bacterial and fungal infections. We identified six descriptive themes organized into two analytic
35	themes. The first analytic theme, social production of risk, considered macro-environmental influences.
36	Four descriptive themes highlighted pathways through which this occurs: (1) unregulated drug supply,
37	leading to poor drug quality and solubility; (2) unsafe spaces, influenced by policing practices and
38	insecure housing; (3) health care policies and practices, leading to negative experiences that discourage
39	access to care; and (4) harm reduction programs, including structural barriers to effective service
40	provision. The second analytic theme, practices of care among people who inject drugs, addresses
41	protective strategies that people who inject drugs employ within infection risk environments. Associated
42	descriptive themes were: (5) mutual care, including assisted-injecting and sharing sterile equipment; and
43	(6) self-care, including vein health and self-treatment. Within constraining risk environments, some
44	protective strategies for bacterial infections precipitated other health risks (e.g., HIV transmission).
45	Conclusions: Injecting-related bacterial and fungal infections are shaped by modifiable social-structural
46	factors, including unregulated drug quality, criminalization, insufficient housing, limited harm reduction

- 47 services, and harmful health care practices. Enabling environment interventions that address these
- 48 factors could further empower people who inject drugs to protect themselves and their community.

49 INTRODUCTION

50	Injection drug use-associated bacterial and fungal infections (e.g. skin and soft-tissue infections,
51	endocarditis, epidural abscess) cause significant morbidity and mortality among people who inject drugs
52	(PWID). ¹⁻⁶ The incidence of hospitalizations for severe injecting-related infections is increasing in
53	Australia, ⁷ Canada, ^{2,8} the United Kingdom (UK), ⁹ and the United States of America (USA). ^{10–14}
54	
55	Efforts to prevent injecting-related bacterial and fungal infections have focused on individual-level
56	behavioural interventions, ^{15,16} including education on hand-washing before drug preparation, ¹⁷ skin-
57	cleaning before injecting, ¹⁸ and avoiding subcutaneous/intramuscular injecting. ¹⁹ While individual-level
58	interventions may be helpful for PWID who can adopt these practices, evaluations of these interventions
59	have shown mixed results ^{20–22} and the incidence of injecting-related infections continues to rise.
60	
61	Risk for injecting-related bacterial and fungal infections likely reflects contributions of multiple factors
62	external to PWID that enable and/or constrain their behaviour and influence health outcomes. ^{23–26}
63	Identifying, measuring, and ameliorating such social-structural factors has informed clinical and public
64	health responses to other drug-related harms, including HIV, ^{27–29} hepatitis C virus (HCV), ³⁰ and
65	overdose. ^{31,32} Understanding the influence of social context on health can broaden awareness of the
66	causes of illness ³³ and inform more appropriate prevention and treatment interventions. ^{29,34,35}
67	
68	Objectives
69	To understand social-structural determinants of injecting-related bacterial and fungal infections and to
70	identify opportunities for potential intervention, we aimed to: (1) systematically review qualitative
71	studies on experiences of injecting-related infections, and (2) synthesize analyses of social-structural

- 72 factors influencing risk for injecting-related infections, their treatment, and subsequent health
- 73 outcomes.
- 74

75 **METHODS**

- 76 Before conducting the search, we published our protocol¹ and registered with PROSPERO
- 77 (CRD42021231411). We modified our original protocol after our search and full-text review. Our
- 78 protocol specified a "mixed studies review" of quantitative, qualitative, and mixed-methods studies.^{38,39}
- 79 As we identified more and richer qualitative sources than anticipated, we decided to consider qualitative
- 80 and quantitative data separately. Here, we report the qualitative systematic review and thematic
- 81 synthesis. Quantitative results will be reported separately. This manuscript follows PRISMA guidelines³⁶
- and the ENTREQ statement³⁷ on qualitative systematic reviews. 82
- 83

Conceptual model and framework 84

The "risk environment", as developed by Rhodes and others, 27,29,40,41 is a socio-ecological model 85 86 describing how macro-environmental (e.g., criminalization; racism) and micro-environmental (e.g., local 87 availability of needle and syringe programs) factors interplay to influence health practices and 88 outcomes.⁴² The risk environment model encourages thinking about how people interact with and 89 modify constraining environments (e.g., drug users' unions organizing to repeal laws banning supervised consumption sites).⁴³ Collins and colleagues recently extended the risk environment to incorporate 90 91 intersectionality, considering how social-structural factors affect PWID differently depending on other social identities and their locations within power hierarchies, including race and gender.⁴² 92 93

- 94 Injecting-related bacterial and fungal infections occur through introducing bacteria or fungi into sterile
- 95 tissues (often from commensal organisms living on the skin) and are precipitated by particulate matter

96	that damages blood vessels, lymphatics, and heart valves. ^{35,44} To conceptualise how the risk
97	environment affects injecting-related infections at different times, we developed a framework (see
98	Figure 1) illustrating a pathway from (a) drug acquisition (e.g. solubility of drugs); (b) drug preparation
99	(e.g. using sterile water to dissolve drugs); (c) drug injection (e.g. accessing veins to avoid intramuscular
100	injecting); (d) development of and care for superficial infections (e.g. self-treatment; primary care); (e)
101	development of and care for severe infections (e.g. hospitalization); and (f) outcomes after infections
102	(e.g. access to follow-up care). ¹ Not all PWID would progress through all stages; some PWID do not
103	develop infections and many who develop infections never access treatment.
104	
105	Eligibility criteria
106	A full description is in our published protocol. ¹ Briefly, we included articles in peer-reviewed journals
107	reporting qualitative studies. We followed the Population, Exposures, Outcomes approach to eligibility
108	criteria. ⁴⁵ The population was PWID (i.e., people injecting any psychoactive substance; excluding people
109	only injecting performance-enhancing or gender-affirming hormones). Exposures were any social or
110	environmental factors that may affect risk of infections, such as housing, service availability, or policing

practices. Outcomes included incidence, treatment, or outcomes of injecting-related bacterial and fungal infections. Eligible studies were published in English or French between January 1, 2000, and February 18, 2021 (to capture contemporary research more likely to inform policy and clinical practice).

114

115 Information sources and search strategy

We searched PubMed, EMBASE, Scopus, CINAHL, and PsycINFO databases. We developed the search
strategy in consultation with a librarian (see Supplementary Table S1 for full search strategy). We
supplemented searches with backward and forward citation chaining and with other studies known to

- the review team (which includes people with lived/past and living/current experience of injection drug
- 120 use, researchers, and clinicians caring for PWID).
- 121

122 Data management and reference selection

- 123 We uploaded titles/abstracts into Covidence software, where they were automatically de-duplicated.
- 124 Two reviewers (TDB and either MB, DL, EC, or IK) independently screened titles/abstracts, resolving
- 125 discrepancies through consensus. We obtained full-text reports for sources that passed screening, and
- 126 one reviewer (TDB) assessed full-text reports.
- 127

128 Quality assessment

- 129 We used the Mixed Methods Appraisal Tool (MMAT), which is a validated and commonly-used appraisal
- 130 tool for mixed studies reviews.^{46,46,47} TDB and EC independently appraised each study, resolving
- 131 discrepancies through discussion. For data synthesis, we included studies meeting both MMAT
- 132 screening questions: "Are there clear research questions?" and "Do the collected data allow to address
- the research questions?"

134

135 Data synthesis

136 Following Thomas and Harden,^{48–51} thematic synthesis comprises three stages: (1) line-by-line open

- 137 coding; (2) organizing codes into descriptive themes reflecting content of studies and study authors'
- 138 interpretations; (3) translating descriptive themes and associated codes across studies to generate
- analytic themes. Coding and generation of descriptive themes focuses on study authors' analysis and
- 140 interpretation because reviewers do not have full knowledge of the original study data.^{48,49}

142	First, TDB (physician and PhD student with qualitative methods training) familiarized himself with the
143	included studies. Next, MB (researcher with lived/living experience of injecting-related infections and a
144	drug policy activist) and TDB independently performed line-by-line coding on the same three
145	purposefully selected, data rich sources. ^{52–54} They compared and contrasted codes and revised them in
146	an iterative, deductive-inductive process, informed by the risk environment model.
147	
148	The whole review team met to provide feedback on these candidate codes: DL (public health specialist),
149	EC and IK (medical students), DW (infectious diseases and addiction medicine physician), AK (infectious
150	disease epidemiologist), and MH (health sociologist with lived experience of injection drug use). TDB
151	coded the remaining papers over several rounds, including adding and revising new candidate codes
152	after discussing with the team at meetings and through collaborative online writing.
153	
154	TDB developed descriptive themes by comparing and contrasting codes across studies, seeking to
155	organize codes into related social-structural categories and proposed them to the team for feedback.
156	TDB then consolidated descriptive themes into conceptual categories to generate analytic themes that
157	were finalized over several iterations and team meetings.
158	
159	RESULTS
160	Following de-duplication, we screened 4,841 titles/abstracts and evaluated 631 full-text reports. After
161	considering 16 additional reports identified outside the search, we identified 151 eligible studies
162	(quantitative, qualitative, and mixed-methods) for our "mixed studies" review. Here, we report on the

- 163 26 studies with qualitative data and analysis (19 qualitative-only and seven mixed-methods). See Figure
- 164 2 for PRISMA diagram. All 26 qualitative studies met our quality criteria for inclusion (see Supplementary
- 165 Table S2 for full MMAT results).

1	6	6
_ T	υ	υ

167 Study characteristics

- 168 See Table 1 for summaries of individual studies. The majority (n=20 studies) were conducted in North
- 169 America. Qualitative data came from individual interviews (n=23), observation/ethnography (n=4), and
- 170 focus groups (n=2). Studies included experiences of injecting-related skin and soft-tissue infections
- 171 (n=22), endocarditis (n=7), bacteremia (n=3), and osteomyelitis (n=2). All 26 studies included bacterial
- infections, and only one study⁵⁵ included fungal infections (candidemia and fungal ophthalmitis).
- 173
- 174 Thematic synthesis
- 175 Summary
- 176 We identified six descriptive themes organized into two analytic themes (see Figure 3).
- 177

178 The first analytic theme, social production of risk, considers how macro-environmental factors, including 179 criminalization, poverty, structural stigma, mandated abstinence, and racism, shape risks for injecting-180 related infections. Four associated descriptive themes highlighted pathways through which this occurs: 181 (1) unregulated drug supply, leading to poor drug guality and solubility; (2) unsafe spaces, influence by 182 insecure housing and policing practices, and ameliorated by supervised consumption sites; (3) health 183 care policies and practices, leading to experiences of discrimination and undertreated pain and 184 withdrawal, which worsened infectious complications by alienating PWID and discouraging access to 185 care; and (4) harm reduction programs, including structural barriers to effective service delivery. 186 187 The second analytic theme, practices of care among people who use drugs, addresses PWID expertise 188 and agency in attempts to prevent and care for bacterial infections within constraining risk 189 environments. Two associated descriptive themes categorized these practices as (5) mutual care,

190	including sharing sterile injecting equipment, assisting others with injecting into veins (rather than
191	intramuscularly), and treating abscesses outside of medical settings; and (6) self-care, including
192	promoting vein health and sourcing safer alternatives when sterile injecting equipment was unavailable.
193	Within constraining risk environments, some of these mutual- and self-care protective strategies for
194	bacterial infections precipitated other health risks, including HIV transmission or arterial injury.
195	
196	Descriptive themes are detailed below, supplemented by quotations from study authors and
197	participants (indicated in italics).
198	
199	Unregulated drug supply
200	In five studies, ^{52,54–57} authors presented perspectives from PWID who attributed infections to the quality
201	of unregulated drugs, including adulterants, ^{52,54,55,57} poor solubility, ^{52,54–57} and bacterial contamination, ⁵⁴
202	especially through precipitating skin abscesses and vein sclerosis. Phillips and colleagues ⁵⁴ reported that
203	PWID in Denver (USA) commonly linked their bacterial infections to poor drug quality:
204	
205	"I think it's the dope because I'll use a clean needle every time, and it still, it just depends on
206	what they cut it with. You know, sometimes when you're cooking it, it's an okay color, and then
207	the next time you're doing it you've got all this shit floating up, and it's all burnt around the
208	sides." (USA) ⁵⁴
209	
210	In two studies, ^{55,57} authors analysed drivers of variation in the unregulated drug supply and associated
211	infection risks. Mars and coauthors ⁵⁷ identified that PWID in Philadelphia (USA) could purchase only tar
212	heroin (which is less soluble than powder heroin, and is associated with greater bacterial infection risk)
213	due to regional demarcation of supply networks. Harris and colleagues ⁵⁵ highlighted London (England)

214	PWID accounts of changing drug quality over time which has impacted widespread overuse of citric acid,
215	which is used to dissolve poorly soluble cutting agents or adulterants such as paracetamol and quinine.
216	
217	Unsafe spaces
218	In eight studies, 53,54,56,58–62 investigators attributed increased bacterial infection risk to suboptimal drug
219	preparation and injecting techniques created by unsafe spaces, including when PWID lacked housing
220	and when trying to avoid being seen by police when using outdoors.
221	
222	In six of these studies, 53,56,58,60,61,63 authors explored influences of being deprived of housing on infection
223	risk. Lack of housing made it harder to prepare and inject drugs safely, including where there were no
224	hygienic surfaces to prepare drugs, ^{53,56,61} inadequate lighting to find veins (leading to "missed hits" and
225	inadvertent subcutaneous injection), ⁵³ and no clean, running water to wash hands/skin or to dissolve
226	drugs (leading PWID to use unhygienic water alternatives) ^{56,58,60,61} :
227	
228	"there was no water actually and I had to use a bit of salivaIt worked, I still got my hit, but I
229	also got the worst infection of my life, I nearly diedYeah, I was in hospital for nearly 3 months.
230	Septicaemia." (England) ⁵⁶
231	
232	In their studies of PWID with endocarditis, Bearnot and colleagues ^{63,64} noted that deprived of housing
233	interfered participants' with care, including being ineligible for outpatient parenteral antimicrobial
234	therapy and having no fixed address for follow-up clinic contacts.
235	
236	In six studies ^{53,54,56,58,59,62} authors analysed how criminalizing possession of drugs or injecting equipment
237	(and associated police enforcement) increased risk for injecting-related infections. When lacking safer

238	indoor places to prepare and consume drugs, participants described engaging in riskier practices to
239	avoid being seen by police. This included preparing and injecting drugs in unhygienic abandoned
240	buildings, ⁵⁸ and compromising injecting preparation practice when hurrying and not using a filter, not
241	using sterile water, and/or inadvertently injecting subcutaneously: ^{53,56,58}
242	
243	"I don't even use cotton [a filter] boom and I usually get it done. Like that. So, if the cops raid
244	and several times the cops have pulled over, come right up to me and I've already injected it in
245	my arm before they hit me." (USA) ⁵³
246	
247	In their ethnography, Bourgois and colleagues ⁵⁹ observed "greater and more antagonistic police
248	surveillance" of African American PWID than of white PWID in San Francisco (USA), leading to racist,
249	differential seizure of sterile syringes (obtained from legal needle and syringe programs). They observed
250	police evict homeless encampments and confiscate possessions, causing PWID to miss medical
251	appointments.
252	
253	Three studies ^{58,65,66} included analyses of how supervised consumption sites create safer spaces to reduce
254	infection risks caused by lack of housing and criminalization, by facilitating individualized education on
255	safer injecting techniques ⁶⁵ and access to wound/abscess care. ^{65,66}
256	
257	Health care policies and practices
258	In 13 studies, authors analysed why PWID delay or avoid medical care for injecting-related infections
259	(often until infections had progressed and spread). Contributing factors were prior experiences of
260	stigmatizing or discriminatory care (in 12 studies ^{53,54,60,61,64,67–73}) and of untreated pain and withdrawal
261	(in six studies ^{53,61,63,64,71,72}). In several studies, PWID described both:

262

263	"I'm not trying to get drugs. I'm trying to get you to take your sharp scalpel, cut this fucking
264	thing open, squeeze this shit out of me, and get me the fuck out of here. That's the pain relief
265	that I want you to give meI can do heroin; your little 5mg Percocet ain't doing nothing for me.
266	But they automatically think when you come in, 'I got an abscess. I'm hurting', 'Oh, you're trying
267	to get drugs', this and that it does prevent a lot of people from going." $(USA)^{53}$
268	
269	Some negative experiences were driven by hospital policies. Harris ⁶¹ explains how a London hospital
270	policy mandates that urine drug screens be obtained before methadone can be dispensed, even if the
271	dose is confirmed by pharmacies or treatment programs. This caused delays or missed dosages of
272	methadone, and resulting experiences of opioid withdrawal led PWID to stay away:
273	
274	"Mainly because how I have been treated at the hospitals, which is just like fucking dirt you'd
275	find on your shoe also being scared that I was going to be rough [sick]because if they didn't
276	[give] me Methadone, like someone's said he [doctor] won't do it unless he would have to, and if
277	you don't know your rights, but yeah, it was that that really scared me more than anything, was
278	being sick [in withdrawal] in a hospital." (England) ⁶¹
279	
280	Four studies ^{60,61,67,69} included analyses of how delays in care due to negative experiences in health care
281	settings had a disproportionate impact by race or gender. Assessing hospital care experiences in
282	Vancouver (Canada), McNeil and colleagues ⁶⁷ described, "Many participants of Aboriginal ancestry
283	further expressed that institutionalized racism reinforced the view among hospital staff that they were
284	'drug-seeking'". Three studies included descriptions of how PWID who were mothers were discouraged
285	from accessing care for injecting-related infections, including feelings of shame at disclosing substance

use as a mother,⁶⁰ and fear of child apprehension if their substance use was reported by health
 professionals.^{61,69}

288

289	In four studies, ^{63,67,70,74} PWID described leaving hospital prematurely, before completing treatment for
290	injecting-related infections. Explanations included leaving hospital in response to discrimination ^{67,74} and
291	because restrictions on their movements in hospital triggered post-traumatic stress. ⁶³ Two studies ^{67,70}
292	highlighted participants being involuntarily discharged from hospital because of drug use, despite
293	ongoing medical need. Jafari and colleagues ⁷⁴ evaluated experiences with a care model intending to
294	overcome these issues: clients at a residential, harm-reduction oriented program for people with severe
295	injecting-related infections in Vancouver, Canada, described receiving less judgmental and stigmatizing
296	care compared to their experience in mainstream hospitals.
297	
298	Only one study specifically explored insufficient health insurance as a barrier to care. ⁶⁹ In other studies,
299	authors explained that insurance is a barrier to health care for some PWID but their study participants
300	had access to public health insurance (universally in Canada ⁶⁷ , and Medicaid in USA ^{63,64}).
301	
302	Harm reduction programs
303	In four studies, ^{52,55,56,71} authors analysed consequences of PWID having insufficient or nonpreferred drug
304	preparation and injecting equipment distributed from harm reduction programs. In their study of
305	experiences of skin and soft-tissue infections in Glasgow (Scotland), Dunleavy and colleagues ⁵² report:
306	"reasons for re-using [needles and syringes included having been] accidentally supplied with the wrong
307	sized needles and preferring to re-use than use the wrong needle". Three of these studies describe
308	PWID lacking needed equipment and repurposing alcohol skin swabs distributed by harm reduction
309	programs: to clean up blood after injecting, ^{52,71} to filter visible particulate matter out of puddle water

310	when lacking access to sterile water, ⁵⁶ and burning swabs to obtain an adequate flame to heat the drug
311	solution when lacking a sufficient lighter. ⁵² In two studies, Harris and colleagues explored how
312	legal/regulatory and funding restrictions on harm reduction programs limited the distribution of sterile
313	water ⁵⁶ or single-use ascorbic acid packets. ⁵⁵
314	
315	In three studies, participants described structural barriers to needle and syringe programs that limited
316	effectiveness. This included limited operating hours (e.g. closures on weekends ⁵²) and restricted
317	eligibility. ^{67,73} McNeil and colleagues ⁶⁷ assessed consequences of PWID being unable to access sterile
318	equipment in hospital, leading to reuse of contaminated equipment:
319	
320	"[Nurses] don't give rigs [syringes] to usI think that they should. If not, we're reusing our rigs
321	or we're having to risk getting kicked out for stealing them or people'll be sharing themI know
322	one girl was using her same rig for days to the point where it was tearing and she was suffering
323	every time she'd do her fix. She just didn't have it in her to go and try and steal clean rigs."
324	(Canada) ⁶⁷
325	
326	Four further studies ^{62,68,75,76} focused on places without local needle and syringe programs (in USA and
327	Mexico), where PWID were also unable to purchase syringes at pharmacies due to refusal from
328	pharmacists:
329	
330	"I think that many [pharmacists] think that by prohibiting the sale of syringes that they are going
331	to stop the usage of drugsbut what they are doing is wrong, because of that we have a harder
332	time finding syringes. We need to use drugs in order to feel well, since when we are in need of a

333	fix we feel desperate enough that we don't care and borrow one from a friend, since it's a
334	desperate feeling" (Mexico) ⁷⁶
335	
336	Paquette and colleagues ⁶⁸ explored how PWID would prefer having multiple access points for sterile
337	injecting equipment, including from both pharmacies and needle and syringe programs: "one
338	participant indicated that using the [needle and syringe program] could out him as a PWID and expose
339	him to stigma from others because [needle and syringe programs] exclusively serve PWID. If PWID could
340	consistently access syringes at a pharmacy without fear of discrimination, some might prefer this option
341	because it offers a higher level of anonymity than [needle and syringe programs]."68
342	
343	Two studies highlighted how suboptimal delivery of OAT after hospital discharge could increase risks for
344	recurrent infections, including involuntary discharge from OAT because of ongoing use, ⁶³ waiting
345	lists, ^{63,64} and a lack of coordination: ⁶⁴
346	
347	"So I had methadone maintenance while I was in the hospital and I did not really have anything
348	lined up when I left [hospital], which, ultimately, could be one of the many reasons why I ended
349	up re-infecting my valve and back in the hospital." (USA) ⁶⁴
350	
351	Mutual care
352	Five studies ^{52,53,60,62,71} included descriptions of PWID caring for each other to promote health and reduce
353	risks of infections. Within constraining risk environments, some of these protective strategies for
354	bacterial infections precipitated other health risks.
355	

356	Mutual care practices include providing or receiving education from fellow PWID, ⁵² sharing sterile
357	needles or injecting equipment in settings of scarcity, ⁶² and offering or receiving assistance with
358	injecting to reduce infection risks ^{53,60} :
359	
360	"I have my boyfriend. I only hit with him, always with him. I do not like to do it with strangers or
361	people to whom I do not know so well My boyfriend helps me, because when I do it, it swells
362	<i>up."</i> (USA) ⁶⁰
363	
364	Once infections developed, study participants described providing or receiving wound care and abscess
365	treatment or antibiotics from peers in order to avoid negative experiences with the health care
366	system. ^{53,71}
367	
368	While navigating risk environments, protective strategies for bacterial infections could precipitate other
369	health risks. For example, three studies ^{55,60,77} assessed particular risks that women PWID face when
370	relying on assisted injecting in the context of gendered power dynamics. In their study, Epele ⁶⁰ explored
371	these trade-offs: "Abscesses and scars that are more frequent with muscle injection lead to further
372	subordination within the hierarchies of their social networks, and deteriorate the women's precarious
373	strategies of income production. Although being injected by another increases the probability of HIV
374	infection, it simultaneously prevents the visible physical damage that subjects these women to greater
375	vulnerability." Similarly, nonmedical abscess treatment or use of potentially inappropriate from
376	nonmedical sources can lead to worsening infections, but PWID described employing these strategies to
377	avoid negative experiences in health care settings. ^{53,71}
378	
379	Self-care

380	Twelve studies ^{52,53,56–58,60,63–65,68,71,76} included analyses of participants' practices to prevent and treat
381	bacterial infections. These included practices to promote vein and skin care, including staying
382	hydrated, ⁷¹ rotating injecting sites, ⁶⁰ taking extra time to access veins, ^{53,57,71} asking for help to access
383	veins, ^{60,77} and self-treating superficial abscesses (e.g., incision and drainage; nonmedical sources of
384	antibiotics) before they progressed. 53,68,71
385	
386	"Little things like drink a lot of liquids, make sure you sleep every night. Make sure you get
387	enough sleep, drink liquids, eat regularly." (USA) ⁷¹
388	
389	In three of these studies, authors highlighted actions to mitigate the risks of poor-quality drugs or
390	injecting equipment, including sharpening the tips of used needle tips to avoid vein damage (when
391	unable to access new needles), ⁷⁶ sourcing safer water by asking passers-by for bottled water, ⁵⁶ and using
392	ascorbic acid (which is safer than citric acid or lemon juice) when preparing heroin. ⁵⁵
393	
394	In five studies, participants also described changing their drug use practices after experiencing an
395	infection, to avoid another one. This included applying new learnings on safer injecting techniques, ^{52,64,65}
396	switching from injecting to smoking, ⁵² getting wounds assessed by a nurse, ⁵² using the minimum
397	required acidifier to dissolve drugs, ⁵⁵ and seeking addiction treatment to reduce or abstain from
398	injection use. ⁶³
399	
400	Three studies included descriptions of self-care practices of PWID to avoid discrimination and structural
401	stigma. This included injecting in central veins at hidden sites to avoid scars at more visible peripheral
402	sites, ^{52,60} and using in unhygienic abandoned buildings to avoid being seen. ⁵⁸
403	

404 Some of these protective self-care strategies employed within constraining risk environments also led to other potential health risks. For example, injecting in central veins in the groin to avoid discrimination 405 406 from visible scars increases risks of thrombosis and arterial injury, and likely increase risks for bacterial 407 infections (as the groin has a higher burden of bacterial colonisation). Considering unintended harms of 408 inappropriate self-treatment of bacterial infections, Gilbert and colleagues⁷¹ write: "There are certainly 409 risks conferred by the self-care practices that PWID are forced to resort to. However, these risks are not 410 taken lightly by PWID; they are weighed against the risk of inaction and worsening infections, which is 411 well known in these communities."

412

413 **DISCUSSION**

414 We reviewed qualitative studies on experiences of injection drug use-associated bacterial and fungal 415 infections, and used thematic synthesis to identify social-structural factors influencing risk for these 416 infections. These include poor quality of unregulated drugs, insufficient housing, policing practices, 417 limited harm reduction services, and harmful health care practices. These are shaped by macro-418 environmental factors including structural stigma, criminalization, government austerity, and racism. We 419 also identified ways in which PWID care for themselves and others to prevent and treat injecting-related 420 infections, including by sharing sterile equipment and treating infections outside of medical settings. 421 Within constraining risk environments, PWID face trade-offs and some of these protective strategies 422 precipitated other health risks (e.g. in some circumstances of assisted-injecting). Enabling environment 423 interventions that address these social-structural factors could further empower people who inject 424 drugs to protect themselves and their community. While the importance of education on safer injecting technique came up in several studies, ^{52,53,55,66,76} our findings suggest that individual-level behavioural 425 426 interventions alone are likely insufficient to reduce risk.

427

428	Several social-structural determinants of bacterial and fungal infections (as well as practices of mutual-
429	and self-care ^{35,78}) that we identified are consistent with prior studies examining risk for HIV and HCV
430	among PWID. ^{27,29,42,79} Insecure housing, hurrying injections to avoid police, insufficient harm reduction
431	services, and laws restricting sterile injecting equipment are known to contribute to HCV ⁷⁹ and HIV ²⁷
432	risks. Stigmatizing and discriminatory health care experiences similarly discourage HCV and HIV
433	treatment access and exacerbate health inequities. ^{30,80} Compared to the literature on HIV and HCV
434	among PWID, ^{81,82} we identified relatively little published research considering intersectionality and risk
435	for injecting-related bacterial or fungal infections. ⁴² A qualitative study by Hrycko and colleagues
436	published after we conducted our search identified several social-structural factors contributing to risk
437	for severe bacterial infections, including availability and use of drugs (e.g. fentanyl, stimulants)
438	associated with a shorter duration of effect and more frequent injecting, and lack of access to sterile
439	water. ⁸³
440	
441	A key motivation for our review was to identify potential opportunities to reduce risks for injecting-
442	related bacterial and fungal infections. Many social-structural factors that we identified are modifiable,
443	and some have already been resolved or ameliorated in some places. These include PWID organizing to
444	access better quality, regulated drugs including via injectable OAT (with liquid formulations of
445	
	diacetylmorphine, hydromorphone, or fentanyl), and through "safe supply" prescribing programs or
446	diacetylmorphine, hydromorphone, or fentanyl), and through "safe supply" prescribing programs or compassion clubs. ^{84–86} Injectable OAT is associated with low risk for bacterial infections even when
446 447	diacetylmorphine, hydromorphone, or fentanyl), and through "safe supply" prescribing programs or compassion clubs. ^{84–86} Injectable OAT is associated with low risk for bacterial infections even when injected intramuscularly, since sterile, liquid formulations of drugs are provided in a hygienic and safe
446 447 448	diacetylmorphine, hydromorphone, or fentanyl), and through "safe supply" prescribing programs or compassion clubs. ^{84–86} Injectable OAT is associated with low risk for bacterial infections even when injected intramuscularly, since sterile, liquid formulations of drugs are provided in a hygienic and safe environment. ⁸⁷ Social and supportive housing (including Housing First) can help PWID access and
446 447 448 449	diacetylmorphine, hydromorphone, or fentanyl), and through "safe supply" prescribing programs or compassion clubs. ^{84–86} Injectable OAT is associated with low risk for bacterial infections even when injected intramuscularly, since sterile, liquid formulations of drugs are provided in a hygienic and safe environment. ⁸⁷ Social and supportive housing (including Housing First) can help PWID access and maintain housing; some models combine housing with injectable OAT, safe supply, and/or supervised
446 447 448 449 450	diacetylmorphine, hydromorphone, or fentanyl), and through "safe supply" prescribing programs or compassion clubs. ^{84–86} Injectable OAT is associated with low risk for bacterial infections even when injected intramuscularly, since sterile, liquid formulations of drugs are provided in a hygienic and safe environment. ⁸⁷ Social and supportive housing (including Housing First) can help PWID access and maintain housing; some models combine housing with injectable OAT, safe supply, and/or supervised consumption sites. ^{88–90} In some jurisdictions PWID and their allies have successfully advocated for

452	Several initiatives have improved health care experiences for PWID with injecting-related infections, ^{92,93}
453	including incorporating harm reduction and cultural safety principles, ^{61,94} specialized addiction medicine
454	consultation services, ^{95–97} needle and syringe programs, ^{98,99} and supervised consumption sites ^{100,101} into
455	hospital care. Policy changes are needed at many hospitals to facilitate these initiatives. ^{102,103}
456	
457	Our study has three key limitations. First, our review only included studies describing experiences of
458	injecting-related infections and we did not include all studies investigating determinants of risky
459	injecting practices (e.g. subcutaneous injecting; reuse of contaminated equipment) unless explicitly
460	connected to infections. Second, we did not include gray literature that might have discussed further
461	social-structural factors beyond those we identified in peer-reviewed papers. Third, some
462	commentators ^{48,104} have argued that qualitative evidence syntheses decontextualize the nuanced
463	findings of qualitative studies (conducted in different settings, with different methods) and try to
464	consolidate knowledge that is not generalizable. We undertook this approach to understand how social
465	and structural factors shape risks for injecting-related infections in ways that may be impossible to
466	assess with quantitative research. ^{38,105}
467	
468	Conclusions
469	Injecting-related bacterial and fungal infections are shaped by modifiable social-structural factors,
470	including unregulated drug quality, criminalization, insufficient housing, limited harm reduction services,
471	and harmful health care practices. Enabling environment interventions that address these factors could
472	further empower people who inject drugs to protect themselves and their community.

473 ACKNOWLEDGMENTS

474	We thank Louise Gillis (Research Data Librarian at Dalhousie University) for helpful feedback and
475	assistance with our search strategy. We thank Drs. Lindsay Wallace (Cambridge University), Ashish
476	Thakrar (University of Pennsylvania), and Paul Christine (Boston Medical Center) for helpful comments
477	on earlier manuscript drafts.
478	
479	We acknowledge that TDB, MB, EC, and IK live and work in Mi'kma'ki, the ancestral and unceded
480	territory of the Mi'kmaq, and DW lives and works in unsurrendered and unceded territory and
481	traditional lands of Wolastoqiyik. This territory is covered by the Treaties of Peace and Friendship which
482	the Mi'kmaq and Wolastoqiyik Peoples first signed with the British Crown in 1725. The treaties did not
483	deal with surrender of lands and resources but in fact recognized Mi'kmaq and Wolastoqiyik title and
484	established the rules for what was to be an ongoing relationship between nations. We are Treaty
485	people.
486	
487	FUNDING
488	TDB is supported by the Dalhousie University Internal Medicine Research Foundation Fellowship, a
489	Canadian Institutes of Health Research Fellowship (CIHR-FRN# 171259), and through the Research in
490	Addiction Medicine Scholars Program (National Institutes of Health/ National Institute on Drug Abuse;
491	R25DA033211). For part of this work, he was supported by the Killam Postgraduate Scholarship, Ross
492	Stewart Smith Memorial Fellowship in Medical Research, and Clinician Investigator Programme
493	Graduate Stipend (all from Dalhousie University Faculty of Medicine). MB, EC, and IK were supported in
494	this work via the Ross Stewart Smith Memorial Fellowship in Medical Research (PI: TDB). DL was funded

495 by a National Institute of Health Research Doctoral Research Fellowship (DRF-2018–11-ST2-016). MH

- 496 was funded by a National Institute of Health Research Career Development Fellowship (CDF-2016-09-
- 497 014).
- 498
- 499 The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the
- 500 Department of Health and Social Care. These funders had no role in the conduct or reporting of the
- 501 research.
- 502
- 503 DECLARATIONS OF COMPETING INTEREST
- 504 MB reports personal fees from AbbVie, a pharmaceutical research and development company, and
- 505 grants and personal fees from Gilead Sciences, a research-based biopharmaceutical company, outside of
- 506 the submitted work. The other authors report no competing interests.

508 **REFERENCES**

- Brothers TD, Lewer D, Bonn M, Webster D, Harris M. Social and structural determinants of injecting-related bacterial and fungal infections among people who inject drugs: protocol for a mixed studies systematic review. BMJ Open. 2021 Aug 9;11(8):e049924.
 http://doi.org/10.1126/hmianen.2021.040024
- 512 http://doi.org/10.1136/bmjopen-2021-049924
- Gomes T, Kitchen SA, Tailor L, Men S, Murray R, Bayoumi AM, et al. Trends in
 Hospitalizations for Serious Infections Among People With Opioid Use Disorder in Ontario,
 Canada. J Addict Med. 2021 Oct 28;Publish Ahead of Print.
 https://doi.org/10.1097/adm.00000000000928
- Serota DP, Bartholomew TS, Tookes HE. Evaluating Differences in Opioid and Stimulant
 Use-associated Infectious Disease Hospitalizations in Florida, 2016–2017. Clin Infect Dis.
 2021 Oct 1;73(7):e1649–57. https://doi.org/10.1093/cid/ciaa1278
- Meisner JA, Anesi J, Chen X, Grande D. Changes in Infective Endocarditis Admissions in
 Pennsylvania During the Opioid Epidemic. Clin Infect Dis. 2020;71(7):1664–70.
 https://doi.org/10.1093/cid/ciz1038
- Lewer D, Freer J, King E, Larney S, Degenhardt L, Tweed EJ, et al. Frequency of healthcare
 utilisation by adults who use illicit drugs: a systematic review and meta-analysis.
 Addiction. 2020 Jun;115(6):1011–23. https://doi.org/10.1111/add.14892
- 526 6. Kim JH, Fine DR, Li L, Kimmel SD, Ngo LH, Suzuki J, et al. Disparities in United States
 527 hospitalizations for serious infections in patients with and without opioid use disorder: A
 528 nationwide observational study. PLoS Med. 2020 Aug 7;17(8):e1003247.
 529 https://doi.org/10.1371/journal.pmed.1003247
- Wright A, Otome O, Harvey C, Bowe S, Athan E. The Current Epidemiology of Injecting
 Drug Use-Associated Infective Endocarditis in Victoria, Australia in the Midst of Increasing
 Crystal Methamphetamine Use. Heart Lung Circ. 2018 Apr 1;27(4):484–8.
 https://doi.org/10.1016/j.hlc.2017.03.166
- Mosseler K, Materniak S, Brothers TD, Webster D. Epidemiology, microbiology, and clinical outcomes among patients with intravenous drug use-associated infective endocarditis in New Brunswick. Can J Cardiol Open. 2020;2(5):379–85.
 https://doi.org/10.1016/j.cjco.2020.05.002
- Lewer D, Harris M, Hope V. Opiate Injection–Associated Skin, Soft Tissue, and Vascular
 Infections, England, UK, 1997–2016. Emerg Infect Dis. 2019 Sep 23;23(8):1400–3.
 https://doi.org/10.3201/eid2308.170439
- Wurcel AG, Anderson JE, Chui KKH, Skinner S, Knox TA, Snydman DR, et al. Increasing
 Infectious Endocarditis Admissions Among Young People Who Inject Drugs. Open Forum
 Infect Dis. 2016 Jul 26;3(3):ofw157. https://doi.org/10.1093/ofid/ofw157

Barocas JA, Eftekhari Yazdi G, Savinkina A, Nolen S, Savitzky C, Samet JH, et al. Long-term
 Infective Endocarditis Mortality Associated With Injection Opioid Use in the United States:
 A Modeling Study. Clin Infect Dis. 2021 Dec 6;73(11):ciaa1346.

- 547 https://doi.org/10.1093/cid/ciaa1346
- McCarthy NL, Baggs J, See I, Reddy SC, Jernigan JA, Gokhale RH, et al. Bacterial Infections
 Associated With Substance Use Disorders, Large Cohort of United States Hospitals, 2012–
 2017. Clin Infect Dis. 2020 Oct 23;71(7):e37–44. https://doi.org/10.1093/cid/ciaa008
- Cooper HLF, Brady JE, Ciccarone D, Tempalski B, Gostnell K, Friedman SR. Nationwide
 Increase in the Number of Hospitalizations for Illicit Injection Drug Use-Related Infective
 Endocarditis. Clin Infect Dis. 2007 Nov 1;45(9):1200–3. https://doi.org/10.1086/522176
- 14. Ronan MV, Herzig SJ. Hospitalizations Related To Opioid Abuse/Dependence And
 Associated Serious Infections Increased Sharply, 2002–12. Health Aff (Millwood). 2016 Jan
 5;35(5):832–7. https://doi.org/10.1377/hlthaff.2015.1424
- Larney S, Peacock A, Mathers BM, Hickman M, Degenhardt L. A systematic review of
 injecting-related injury and disease among people who inject drugs. Drug Alcohol Depend.
 2017 Feb 1;171:39–49. https://doi.org/10.1016/j.drugalcdep.2016.11.029
- 560 16. Gordon RJ, Lowy FD. Bacterial Infections in Drug Users. N Engl J Med. 2005 Nov
 561 3;353(18):1945-54. https://doi.org/10.1056/NEJMra042823

562 17. Dwyer R, Topp L, Maher L, Power R, Hellard M, Walsh N, et al. Prevalences and correlates
563 of non-viral injecting-related injuries and diseases in a convenience sample of Australian
564 injecting drug users. Drug Alcohol Depend. 2009 Feb 1;100(1):9–16.
565 https://doi.org/10.1016/j.drugalcdep.2008.08.016

- Hope VD, Hickman M, Parry JV, Ncube F. Factors associated with recent symptoms of an
 injection site infection or injury among people who inject drugs in three English cities. Int J
 Drug Policy. 2014 Mar 1;25(2):303–7. https://doi.org/10.1016/j.drugpo.2013.11.012
- Phillips KT, Stein MD. Risk Practices Associated with Bacterial Infections among Injection
 Drug Users in Denver, Colorado. Am J Drug Alcohol Abuse. 2010 Mar 1;36(2):92–7.
 https://doi.org/10.3109/00952991003592311
- Roux P, Donadille C, Magen C, Schatz E, Stranz R, Curano A, et al. Implementation and
 evaluation of an educational intervention for safer injection in people who inject drugs in
 Europe: a multi-country mixed-methods study. Int J Drug Policy. 2021 Jan 1;87:102992.
 https://doi.org/10.1016/j.drugpo.2020.102992
- 576 21. Stein MD, Phillips KT, Herman DS, Keosaian J, Stewart C, Anderson BJ, et al. Skin-cleaning
 577 among hospitalized people who inject drugs: a randomized controlled trial. Addiction.
 578 2021 May;116(5):122–1130. https://doi.org/10.1111/add.15236

Phillips KT, Stewart C, Anderson BJ, Liebschutz JM, Herman DS, Stein MD. A randomized
controlled trial of a brief behavioral intervention to reduce skin and soft tissue infections
among people who inject drugs. Drug Alcohol Depend. 2021 Feb 27;108646.
https://doi.org/10.1016/j.drugalcdep.2021.108646

- 583 23. Harvey M. The Political Economy of Health: Revisiting Its Marxian Origins to Address 21st584 Century Health Inequalities. Am J Public Health. 2021 Feb;111(2):293–300.
 585 https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2020.305996
- 586 24. Holman D, Lynch R, Reeves A. How do health behaviour interventions take account of
 587 social context? A literature trend and co-citation analysis. Health (N Y). 2018 Jul
 588 1;22(4):389–410. https://doi.org/10.1177/1363459317695630
- 589 25. Link BG, Phelan J. Social Conditions As Fundamental Causes of Disease. J Health Soc Behav.
 590 1995;35:80. https://doi.org/10.2307/2626958
- 591 26. Krieger N. Theories for social epidemiology in the 21st century: an ecosocial perspective.
 592 Int J Epidemiol. 2001 Aug 1;30(4):668–77. https://doi.org/10.1093/ije/30.4.668
- 593 27. Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, Abdool R, et al. HIV and risk
 594 environment for injecting drug users: the past, present, and future. Lancet Lond Engl. 2010
 595 Jul 24;376(9737):268–84. https://doi.org/10.1016/s0140-6736(10)60743-x
- 28. Rhodes T, Simic M. Transition and the HIV risk environment. BMJ. 2005 Jul
 23;331(7510):220–3. https://doi.org/10.1136/bmj.331.7510.220
- Searching
 29. Rhodes T, Singer M, Bourgois P, Friedman SR, Strathdee SA. The social structural
 production of HIV risk among injecting drug users. Soc Sci Med. 2005 Sep 1;61(5):1026–44.
 https://doi.org/10.1016/j.socscimed.2004.12.024
- 30. Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs:
 a review mapping the role of social factors. Harm Reduct J. 2013 May 7;10(1):7.
 https://doi.org/10.1186/1477-7517-10-7
- Basgupta N, Beletsky L, Ciccarone D. Opioid Crisis: No Easy Fix to Its Social and Economic
 Determinants. Am J Public Health. 2017 Dec 21;108(2):182–6.
 https://doi.org/10.2105/ajph.2017.304187
- McLean K. "There's nothing here": Deindustrialization as risk environment for overdose.
 Int J Drug Policy. 2016 Mar 1;29:19–26. https://doi.org/10.1016/j.drugpo.2016.01.009
- Amemiya J, Mortenson E, Heyman GD, Walker CM. Thinking Structurally: A Cognitive
 Framework for Understanding How People Attribute Inequality to Structural Causes.
- 611 Perspect Psychol Sci. 2022 Aug 18;17456916221093592.
- 612 https://doi.org/10.1177/17456916221093593

- 613 34. McNeil R, Small W. 'Safer environment interventions': A qualitative synthesis of the
- experiences and perceptions of people who inject drugs. Soc Sci Med. 2014 Apr;106:151–
 8. https://doi.org/10.1016/j.socscimed.2014.01.051
- 616 35. Harris M, Rhodes T. Venous access and care: harnessing pragmatics in harm reduction for
- 617 people who inject drugs. Addiction. 2012 Jun;107(6):1090–6.
- 618 https://doi.org/10.1111/j.1360-0443.2011.03749.x
- 619 36. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA
 620 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar
 621 29;372:n71. https://doi.org/10.1136/bmj.n71
- Tong A, Flemming K, McInnes E, Oliver S, Craig J. Enhancing transparency in reporting the
 synthesis of qualitative research: ENTREQ. BMC Med Res Methodol. 2012 Nov
 27;12(1):181. https://doi.org/10.1186/1471-2288-12-181
- 38. Pluye P, Hong QN. Combining the Power of Stories and the Power of Numbers: Mixed
 Methods Research and Mixed Studies Reviews. Annu Rev Public Health. 2014;35(1):29–45.
 https://doi.org/10.1146/annurev-publhealth-032013-182440
- 39. Pluye P, Hong QN, Bush PL, Vedel I. Opening-up the definition of systematic literature
 review: the plurality of worldviews, methodologies and methods for reviews and
 syntheses. J Clin Epidemiol. 2016 May 1;73:2–5.
 https://doi.org/10.1016/i.iclinopi.2015.08.022
- 631 https://doi.org/10.1016/j.jclinepi.2015.08.033
- 632 40. Rhodes T. The 'risk environment': a framework for understanding and reducing drug633 related harm. Int J Drug Policy. 2002 Jun 1;13(2):85–94. https://doi.org/10.1016/S0955634 3959(02)00007-5
- 635 41. Rhodes T. Risk environments and drug harms: A social science for harm reduction
 636 approach. Int J Drug Policy. 2009 May 1;20(3):193–201.
 637 https://doi.org/10.1016/j.drugpo.2008.10.003
- 638 42. Collins AB, Boyd J, Cooper HLF, McNeil R. The intersectional risk environment of people
 639 who use drugs. Soc Sci Med. 2019 Aug 1;234:112384.
 640 https://doi.org/10.1016/j.socscimed.2019.112384
- Rhodes T, Wagner K, Strathdee SA, Shannon K, Davidson P, Bourgois P. Structural Violence
 and Structural Vulnerability Within the Risk Environment: Theoretical and Methodological
 Perspectives for a Social Epidemiology of HIV Risk Among Injection Drug Users and Sex
 Workers. In: O'Campo P, Dunn JR, editors. Rethinking Social Epidemiology: Towards a
 Science of Change. Dordrecht: Springer Netherlands; 2012. p. 205–30.
 https://doi.org/10.1007/978-94-007-2138-8 10
- 647 44. Robertson R, Broers B, Harris M. Injecting drug use, the skin and vasculature. Addiction.
 648 2021 Jul;116(7):add.15283. https://doi.org/10.1111/add.15283

45. Moola S, Munn Z, Sears K, Sfetcu R, Currie M, Lisy K, et al. Conducting systematic reviews
of association (etiology): The Joanna Briggs Institute's approach. JBI Evid Implement. 2015
Sep;13(3):163–9. https://doi.org/10.1097/xeb.0000000000064

- 46. Hong QN, Fàbregues S, Bartlett G, Boardman F, Cargo M, Dagenais P, et al. The Mixed
 Methods Appraisal Tool (MMAT) version 2018 for information professionals and
 researchers. Educ Inf. 2018 Jan 1;34(4):285–91.
- 655 https://content.iospress.com/articles/education-for-information/efi180221
- 47. Hong QN, Pluye P. A Conceptual Framework for Critical Appraisal in Systematic Mixed
 Studies Reviews. J Mix Methods Res. 2019 Oct 1;13(4):446–60.
 https://doi.org/10.1177/1558689818770058
- 48. Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in
 systematic reviews. BMC Med Res Methodol. 2008 Jul 10;8(1):45.
 https://doi.org/10.1186/1471-2288-8-45
- Guise A, Horyniak D, Melo J, McNeil R, Werb D. The experience of initiating injection drug
 use and its social context: a qualitative systematic review and thematic synthesis.
 Addiction. 2017;112(12):2098–111. https://doi.org/10.1111/add.13957
- 50. Harris M, Guy D, Picchio CA, White TM, Rhodes T, Lazarus JV. Conceptualising hepatitis C
 stigma: A thematic synthesis of qualitative research. Int J Drug Policy. 2021 Oct
 1;96:103320. https://doi.org/10.1016/j.drugpo.2021.103320
- 51. Yoon GH, Levengood TW, Davoust MJ, Ogden SN, Kral AH, Cahill SR, et al. Implementation
 and sustainability of safe consumption sites: a qualitative systematic review and thematic
 synthesis. Harm Reduct J. 2022 Jul 5;19(1):73. https://doi.org/10.1186/s12954-022-00655z
- 52. Dunleavy K, Hope V, Roy K, Taylor A. The experiences of people who inject drugs of skin
 and soft tissue infections and harm reduction: A qualitative study. Int J Drug Policy.
 2019;65:65–72. https://doi.org/10.1016/j.drugpo.2018.09.001
- 53. Harris RE, Richardson J, Frasso R, Anderson ED. Experiences with skin and soft tissue
 infections among people who inject drugs in Philadelphia: A qualitative study. Drug
 Alcohol Depend. 2018 Jun 1;187:8–12. https://doi.org/10.1016/j.drugalcdep.2018.01.029
- 54. Phillips KT, Altman JK, Corsi KF, Stein MD. Development of a risk reduction intervention to
 reduce bacterial and viral infections for injection drug users. Subst Use Misuse. 2013
 Jan;48(1-2):54-64.
- 55. Harris M, Scott J, Wright T, Brathwaite R, Ciccarone D, Hope V. Injecting-related health
 harms and overuse of acidifiers among people who inject heroin and crack cocaine in
 London: a mixed-methods study. Harm Reduct J. 2019 Nov 13;16(1):60.
 https://doi.org/10.1186/s12954-019-0330-6

56. Harris M, Scott J, Hope V, Wright T, McGowan C, Ciccarone D. Navigating environmental
constraints to injection preparation: the use of saliva and other alternatives to sterile
water among unstably housed PWID in London. Harm Reduct J. 2020 Apr 10;17(1):24.
https://doi.org/10.1186/s12954-020-00369-0

- 57. Mars SG, Bourgois P, Karandinos G, Montero F, Ciccarone D. The Textures of Heroin: User
 Perspectives on "Black Tar" and Powder Heroin in Two U.S. Cities. J Psychoact Drugs.
 2016;48(4):270–8. https://doi.org/10.1080/02791072.2016.1207826
- 692 58. Harris RE, Richardson J, Frasso R, Anderson ED. Perceptions about supervised injection
 693 facilities among people who inject drugs in Philadelphia. Int J Drug Policy. 2018;52:56–61.
- 694 59. Bourgois P, Martinez A, Kral A, Edlin BR, Schonberg J, Ciccarone D. Reinterpreting ethnic
 695 patterns among white and African American men who inject heroin: a social science of
 696 medicine approach. PLoS Med. 2006 Oct;3(10):e452.
- 69760.Epele ME. Scars, harm and pain: About being injected among drug using Latina women. J698Ethn Subst Abuse. 2002;1(1):47–69. https://doi.org/10.1300/J233v01n01_04
- 699 61. Harris M. Normalised pain and severe health care delay among people who inject drugs in
 700 London: Adapting cultural safety principles to promote care. Soc Sci Med. 2020 Sep
 701 1;260:113183. https://doi.org/10.1016/j.socscimed.2020.113183
- Pollini RA, Paquette CE, Slocum S, LeMire D. 'It's just basically a box full of disease'navigating sterile syringe scarcity in a rural New England state. Addict Abingdon Engl. 2021
 Jan;116(1):107–15. https://doi.org/10.1111/add.15113
- Bearnot B, Mitton JA. "You're Always Jumping Through Hoops": Journey Mapping the Care
 Experiences of Individuals With Opioid Use Disorder-associated Endocarditis. J Addict
 Med. 2020 Apr 7;Publish Ahead of Print. https://doi.org/10.1097/adm.00000000000648
- 64. Bearnot B, Mitton JA, Hayden M, Park ER. Experiences of care among individuals with
 opioid use disorder-associated endocarditis and their healthcare providers: Results from a
 qualitative study. J Subst Abuse Treat. 2019 Jul 1;102:16–22.
 https://doi.org/10.1016/j.jsat.2019.04.008
- Krüsi A, Small W, Wood E, Kerr T. An integrated supervised injecting program within a care
 facility for HIV-positive individuals: a qualitative evaluation. AIDS Care. 2009
 May;21(5):638–44. https://doi.org/10.1080/09540120802385645
- 66. Small W, Wood E, Lloyd-Smith E, Tyndall M, Kerr T. Accessing care for injection-related
 infections through a medically supervised injecting facility: A qualitative study. Drug
 Alcohol Depend. 2008 Nov 1;98(1):159–62.
- 718 https://doi.org/10.1016/j.drugalcdep.2008.05.014

719 67. McNeil R, Small W, Wood E, Kerr T. Hospitals as a "risk environment": An ethno-720 epidemiological study of voluntary and involuntary discharge from hospital against 721 medical advice among people who inject drugs. Soc Sci Med. 2014 Mar;105:59–66. 722 https://doi.org/10.1016/j.socscimed.2014.01.010 723 68. Paquette CE, Syvertsen JL, Pollini RA. Stigma at every turn: Health services experiences 724 among people who inject drugs. Int J Drug Policy. 2018 Jul;57:104–10. 725 https://doi.org/10.1016/j.drugpo.2018.04.004 726 69. Colwill JP, Sherman MI, Siedlecki SL, Burchill CN, Siegmund LA. A grounded theory 727 approach to the care experience of patients with intravenous drug use/abuse-related 728 endocarditis. Appl Nurs Res. 2021;57:N.PAG-N.PAG. 729 https://doi.org/10.1016/j.apnr.2020.151390 730 70. Bodkin K, Delahunty-Pike A, O'Shea T. Reducing stigma in healthcare and law 731 enforcement: A novel approach to service provision for street level sex workers. Int J 732 Equity Health. 2015;14(1). https://doi.org/10.1186/s12939-015-0156-0 733 71. Gilbert AR, Hellman JL, Wilkes MS, Rees VW, Summers PJ. Self-care habits among people 734 who inject drugs with skin and soft tissue infections: a qualitative analysis. Harm Reduct J. 735 2019 Dec 12;16(1):69. https://doi.org/10.1186/s12954-019-0345-z 736 72. Summers PJ, Hellman JL, MacLean MR, Rees VW, Wilkes MS. Negative experiences of pain 737 and withdrawal create barriers to abscess care for people who inject heroin. A mixed 738 methods analysis. Drug Alcohol Depend. 2018 Sep 1;190:200-8. https://doi.org/10.1016/j.drugalcdep.2018.06.010 739 740 73. Meyer JP, Culbert GJ, Azbel L, Bachireddy C, Kurmanalieva A, Rhodes T, et al. A qualitative 741 study of diphenhydramine injection in Kyrgyz prisons and implications for harm reduction. 742 Harm Reduct J. 2020;17(1):86. https://doi.org/10.1186/s12954-020-00435-7 743 74. Jafari S, Joe R, Elliot D, Nagji A, Hayden S, Marsh DC. A Community Care Model of 744 Intravenous Antibiotic Therapy for Injection Drug Users with Deep Tissue Infection for "Reduce Leaving Against Medical Advice." Int J Ment Health Addict. 2015;13:49–58. 745 746 https://doi.org/10.1007/s11469-014-9511-4 747 75. Case P, Ramos R, Brouwer KC, Firestone-Cruz M, Pollini RA, Fraga MA, et al. At the borders, 748 on the edge: use of injected methamphetamine in Tijuana and Ciudad Juarez, Mexico. J 749 Immigr Minor Health. 2008 Feb;10(1):23–33. https://doi.org/10.1007/s10903-007-9051-0 750 76. Pollini RA, Lozada R, Gallardo M, Rosen P, Vera A, Macias A, et al. Barriers to pharmacy-751 based syringe purchase among injection drug users in Tijuana, Mexico: a mixed methods 752 study. AIDS Behav. 2010 Jun;14(3):679-87. https://doi.org/10.1007/s10461-010-9674-3

753 754 755	77.	Sheard L, Tompkins C. Contradictions and Misperceptions: An Exploration of Injecting Practice, Cleanliness, Risk, and Partnership in the Lives of Women Drug Users. Qual Health Res. 2008 Nov 1;18(11):1536–47. https://doi.org/10.1177/1049732308325838
756 757 758	78.	Kolla G, Strike C. Practices of care among people who buy, use, and sell drugs in community settings. Harm Reduct J. 2020 May 7;17(1):27. https://doi.org/10.1186/s12954-020-00372-5
759 760 761	79.	Rhodes T, Treloar C. The social production of hepatitis C risk among injecting drug users: a qualitative synthesis. Addiction. 2008 Oct;103(10):1593–603. https://doi.org/10.1111/j.1360-0443.2008.02306.x
762 763 764	80.	Krüsi A, Wood E, Montaner J, Kerr T. Social and structural determinants of HAART access and adherence among injection drug users. Int J Drug Policy. 2010 Jan 1;21(1):4–9. https://doi.org/10.1016/j.drugpo.2009.08.003
765 766 767	81.	Bluthenthal RN. Structural racism and violence as social determinants of health: Conceptual, methodological and intervention challenges. Drug Alcohol Depend. 2021 May;222:108681. https://doi.org/10.1016/j.drugalcdep.2021.108681
768 769 770	82.	Touesnard N, Brothers TD, Bonn M, Edelman EJ. Overdose deaths and HIV infections among people who use drugs: shared determinants and integrated responses. Expert Rev Anti Infect Ther. 2022 May 26;0(0):1–5. https://doi.org/10.1080/14787210.2022.2081152
771 772 773	83.	Hrycko A, Mateu-Gelabert P, Ciervo C, Linn-Walton R, Eckhardt B. Severe bacterial infections in people who inject drugs: the role of injection-related tissue damage. Harm Reduct J. 2022 May 2;19(1):41. https://doi.org/10.1186/s12954-022-00624-6
774 775 776 777	84.	Bonn M, Palayew A, Bartlett S, Brothers TD, Touesnard N, Tyndall M. Addressing the Syndemic of HIV, Hepatitis C, Overdose, and COVID-19 Among People Who Use Drugs: The Potential Roles for Decriminalization and Safe Supply. J Stud Alcohol Drugs. 2020 Sep 1;81(5):556–60. https://doi.org/10.15288/jsad.2020.81.556
778 779 780 781 782	85.	BCCSU. Heroin Compassion Clubs: A cooperative model to reduce opioid overdose deaths & disrupt organized crime's role in fentanyl, money laundering & housing unaffordability [Internet]. Vancouver, B.C.: British Columbia Centre on Substance Use.; https://www.bccsu.ca/wp-content/uploads/2019/02/Report-Heroin-Compassion- Clubs.pdf
783 784	86.	Canadian Association of People Who Use Drugs (CAPUD). Safe Supply Concept Document [Internet]. 2019 Feb. https://doi.org/10.5281/zenodo.5637607
785 786 787 788	87.	Meyer M, Eichenberger R, Strasser J, Dürsteler KM, Vogel M. «One prick and then it's done»: a mixed-methods exploratory study on intramuscular injection in heroin-assisted treatment. Harm Reduct J. 2021 Dec 18;18(1):134. https://doi.org/10.1186/s12954-021-00584-3

88. Harris MT, Seliga RK, Fairbairn N, Nolan S, Walley AY, Weinstein ZM, et al. Outcomes of
Ottawa, Canada's Managed Opioid Program (MOP) where supervised injectable
hydromorphone was paired with assisted housing. Int J Drug Policy. 2021 Dec

- 792 1;98:103400. https://doi.org/10.1016/j.drugpo.2021.103400
- 89. Brothers TD, Leaman M, Bonn M, John Fraser, Amy Gillis, Michael Gniewek, et al.
 Evaluation of an emergency safe supply drugs and managed alcohol program in COVID-19
 isolation hotel shelters for people experiencing homelessness. Drug Alcohol Depend. 2022
 Jun 1;235:109440. https://doi.org/10.1016/j.drugalcdep.2022.109440
- 90. Bardwell G, Collins AB, McNeil R, Boyd J. Housing and overdose: an opportunity for the
 scale-up of overdose prevention interventions? Harm Reduct J. 2017 Dec 6;14(1):77.
 https://doi.org/10.1186/s12954-017-0203-9
- 91. McNeil R, Small W, Lampkin H, Shannon K, Kerr T. "People Knew They Could Come Here to
 Get Help": An Ethnographic Study of Assisted Injection Practices at a Peer-Run
 'Unsanctioned' Supervised Drug Consumption Room in a Canadian Setting. AIDS Behav.
 2014 Mar 1;18(3):473–85. https://doi.org/10.1007/s10461-013-0540-y
- 804 92. Brothers TD, Fraser J, Webster D. Caring for people who inject drugs when they are
 805 admitted to hospital. CMAJ Can Med Assoc J. 2021 Mar 22;193(12):E423–4.
 806 https://doi.org/10.1503/cmaj.202124
- 807 93. CRISM. Guidance Document on the Management of Substance Use in Acute Care
 808 [Internet]. Alberta: Canadian Research Initiative on Substance Misuse (CRISM) Prairie
 809 Node; 2020. https://crismprairies.ca/management-of-substance-use-in-acute-care810 settings-in-alberta-guidance-document/
- 94. McCall J, Pauly B. Sowing a Seed of Safety: Providing Culturally Safe Care in Acute Care
 Settings for People who use Drugs. J Ment Health Addict Nurs. 2019 May 31;3(1):e1–7.
 https://doi.org/10.22374/jmhan.v3i1.33
- 814 95. Englander H, Englander H. "We've Learned It's a Medical Illness, Not a Moral Choice":
 815 Qualitative Study of the Effects of a Multicomponent Addiction Intervention on Hospital
 816 Providers' Attitudes and Experiences. J Hosp Med. 2018 Nov 1;13(11).
 817 black (Idea and Intervention 2002)
- 817 https://doi.org/10.12788/jhm.2993
- 818 96. Brothers T, Fraser J, MacAdam E, Hickcox S, L Genge, T O'Donnell, et al. Implementation
 819 and evaluation of a novel, unofficial, trainee-organized hospital addiction medicine
 820 consultation service. Subst Abuse. 2021;42(4):433–7.
 821 https://doi.org/10.1080/08897077.2020.1856291
- 822 97. Hyshka E, Morris H, Anderson-Baron J, Nixon L, Dong K, Salvalaggio G. Patient perspectives
 823 on a harm reduction-oriented addiction medicine consultation team implemented in a

- 824 large acute care hospital. Drug Alcohol Depend. 2019 Nov 1;204:107523.
- 825 https://doi.org/10.1016/j.drugalcdep.2019.06.025
- 826 Brooks HL, O'Brien DC, Salvalaggio G, Dong K, Hyshka E. Uptake into a bedside needle and 98. 827 syringe program for acute care inpatients who inject drugs. Drug Alcohol Rev. 828 2019;38(4):423-7. https://doi.org/10.1111/dar.12930
- 829 99. Brothers TD, Mosseler K, Kirkland S, Melanson P, Barrett L, Webster D. Unequal access to
- 830 opioid agonist treatment and sterile injecting equipment among hospitalized patients with 831 injection drug use-associated infective endocarditis. PLoS ONE. 2022 Jan
- 832 26;17(1):e0263156. https://doi.org/10.1371/journal.pone.0263156
- 833 100. Dong KA, Brouwer J, Johnston C, Hyshka E. Supervised consumption services for acute care 834 hospital patients. CMAJ. 2020 May 4;192(18):E476-9.
- 835 https://doi.org/10.1503/cmaj.191365
- 836 101. Dogherty E, Patterson C, Gagnon M, Harrison S, Chase J, Boerstler J, et al. Implementation 837 of a nurse-led overdose prevention site in a hospital setting: lessons learned from St. 838 Paul's Hospital, Vancouver, Canada. Harm Reduct J. 2022 Feb 5;19(1):13. 839 https://doi.org/10.1186/s12954-022-00596-7
- 840 102. Lennox R, Martin L, Brimner C, O'Shea T. Hospital policy as a harm reduction intervention 841 for people who use drugs. Int J Drug Policy. 2021 Nov 1;97:103324. 842 https://doi.org/10.1016/j.drugpo.2021.103324
- 843 103. Harris M, Holland A, Lewer D, Brown M, Eastwood N, Sutton G, et al. Barriers to 844 management of opioid withdrawal in hospitals in England: a document analysis of hospital 845 policies on the management of substance dependence. BMC Med. 2022 Apr 14;20(1):151. 846 https://doi.org/10.1186/s12916-022-02351-y
- 847 104. Dixon-Woods M, Bonas S, Booth A, Jones DR, Miller T, Sutton AJ, et al. How can systematic 848 reviews incorporate qualitative research? A critical perspective. Qual Res. 2006 Feb 849 1;6(1):27–44. https://doi.org/10.1177/1468794106058867
- 850 105. Bjerre-Nielsen A, Glavind KL. Ethnographic data in the age of big data: How to compare
- 851 and combine. Big Data Soc. 2022 Jan 1;9(1):20539517211069892.
- https://doi.org/10.1177/20539517211069893 852
- 853

854 TABLES Table 1. Summary of included studies.

Study	Country	Qualitative study design	Sample	Focus of interviews/analysis	Conceptual or explanatory model(s)	Summary of findings
Bearnot 2019 ⁶⁴	USA	Individual interviews Grounded theory	11 PWID with opioid injection- associated endocarditis 55% women; median age 38 years; 55% with "unstable housing"	Experiences of endocarditis care	None specified	Poor health outcomes among PWID with opioid injection-associated endocarditis are caused by stigma, delays or discontinuity of care, social and medical comorbidities, perceptions of addiction as a chronic and relapsing disease, and prolonged hospitalizations
Bearnot 2020 ⁶³	USA	Secondary analysis of interview data from Bearnot 2019 ⁶⁴ Journey mapping analysis Grounded theory	Same as Bearnot 2019	Patterns of care for endocarditis	None specified	People with opioid injection- associated endocarditis left care before medically advised because of poor care experiences, including undertreatment of withdrawal and pain and discrimination from clinicians. Following hospitalization, participants commonly engaged in outpatient addiction treatment and follow-up endocarditis care. Leaving outpatient addiction treatment often preceded rehospitalizations with recurrent infections.
Bodkin 2015 ⁷⁰	Canada	Individual interviews Qualitative descriptive analysis	14 PWID recruited from an outreach program for sex workers in London, Ontario	Access to health care among PWID who do sex work	None specified	Sex workers who inject drugs avoided primary care and emergency department treatment of injecting- related infections because of experiences of stigmatization and

		1	1		1	
			100% women; age range 23-49 years; housing status not reported			criminalization. Participants experienced involuntary discharge from hospital and received suboptimal oral antibiotics because of abstinence- requiring policies in hospital.
Bourgois 2006 ⁵⁹	USA	Mixed methods Participant-observation ethnography (field notes, interviews, photographs)	Sample not specifically described, but includes African American and white men who inject heroin in San Franciso, California	How social- structural determinants interface with drug consumption practices and survival strategies among African American and white PWID	"a social science theoretical understanding of the link between large-scale power relations and individual risky practices that shape the spread of blood-borne disease among injectors."	Higher rates of abscesses among white PWID compared to African American PWID reflect socially produced differences in norms between racial/ethnic groups, including social acceptability of subcutaneous injecting among white PWID. Conversely, police are more likely to repeatedly search and confiscate sterile injecting equipment from African American PWID.
Case 2008 ⁷⁵	Mexico	Individual interviews Thematic content analysis	43 PWID recruited through street-based outreach, shooting galleries, and drug treatment programs in Tijuana (n=20) and Ciudad Juárez (n=23) 42% women; median age 30; 30% lived or slept	Injection methamphetamine use in two Mexican border cities	Structural vulnerability	Greater availability of methamphetamine in Tijuana is associated with widespread use, compared to Ciudad Juárez. Injecting methamphetamine is perceived to be associated with increased risk of injecting-site abscesses, described more commonly in Tijuana.

			"on streets" in			
			past six months			
Colwill 2021 ⁶⁹	USA	Individual interviews Grounded theory	11 PWID undergoing surgical evaluation for injecting-related endocarditis 45% women; mean age 31; 9% "Homeless"	Experiences of endocarditis	"PWID with Endocarditis Cyclical Experiences (PEaCE) model"	PWID with endocarditis avoid health care because of stigmatizing and discriminatory experiences. The experience of endocarditis motivated some participants to enter addiction treatment and pursue abstinence.
Dunleavy 2019 ⁵²	Scotland	Individual interviews Framework analysis	22 PWID who had experienced a skin and soft- tissue infection within past year, recruited from needle and syringe program (Glasgow; n=14) or drug treatment service (Edinburgh; n=8) 32% women; median 36 years; 59% experienced homelessness during the past six months	Experiences of skin and soft-tissue infections	Rhodes' risk environment	Stigma associated with skin and soft- tissue infections motivated some participants to try to reduce risks, including use of sterile equipment and safer injecting techniques. No participants had learned about infections and associated risks from harm reduction programs. Social and environmental factors contributing to infection risk included insufficient access to sterile injecting equipment, caustic adulterants in the local drug supply, and a lack of hygienic spaces to prepare and consume drugs.
Epele 2002 ⁶⁰	USA	Individual interviews, observations, and	35 PWID recruited through syringe service	Risk conditions and care practices related to HIV	Political economy of health	Some women who inject drugs rely on injecting assistance from others to avoid intramuscular injection and

		participation in everyday life settings Analysis approach not specified	program and snowball sampling 71% women; mean age of women was 34; all "do not consider themselves as homeless"	among Latino women	Biopower	associated abscesses and scars, because these lead to loss of social status and negatively affect relationships and potential income generation through sex work. Participants recognized that assisted- injecting increases risks for HIV infection. Injection assistance is provided by friends, romantic or sexual partners, and paid "hit doctors".
Gilbert 2019 ⁷¹	USA	Secondary analysis of interview data from Summers 2018 ⁷² Thematic analysis	Same sample as qualitative sample in Summers 2018 ⁷² 12 clients of a syringe services program in Boston (n=6) and Sacramento (n=6) 25% women; median 46 years; housing status not reported	Experience of skin and soft-tissue infections	Health belief model (HBM) of health-seeking behaviors Conceptual Model of Medical Care Avoidance	PWID had good knowledge about skin infections and avoided formal health care due to traumatic experiences, discrimination, and unnecessarily painful procedures. Participants described multiple strategies for prevention and treatment of injecting- related infections including hydration, topical applications, non-prescribed antibiotics, and incision and drainage by non-medical providers.
Harris RE 2018a ⁵³	USA	Individual interviews Analysis approach not specified	19 clients of a syringe services program in Philadelphia 53% women; median age 39 [27-59 years];	Experiences of skin and soft-tissue infections	None specified	PWID described good knowledge about risks of injecting-related skin infections, but were prevented from using hygienic techniques as they lacked of safe places to use drugs. Participants therefore injected abandoned buildings or outdoors, with inadequate lighting, or fear of assault

			housing status not reported			or arrest, leading to drug contamination and intramuscular injection. Participants tended to avoid medical care for injecting-related infections due to prior negative healthcare experiences, including stigma and inadequate treatment of withdrawal and pain. Some participants described self-treatment of infections, including increased drug use for pain control and performing incision and drainage on themselves.
Harris RE 2018b ⁵⁸	USA	Individual interviews Thematic analysis	Same sample as Harris RE 2018a ⁵³ . 19 clients of a syringe services program in Philadelphia. 53% women; median 39 years; housing status not reported	Perceptions of safe injecting facilities	Rhodes' risk environment	PWID described commonly being forced to inject in public spaces, which led them to rush and inject intramuscularly or subcutaneously for fear of assault or arrest. Participants supported the idea of a supervised injection site to reduce these risks and inject more safely. Participants with stable housing preferred to inject at home and described that this reduced risks of injecting-related infections due to less fear of assault or arrest, adequate light and heat, running water, and space to store sterile injecting equipment.
Harris M 2019 ⁵⁵	England	Mixed methods Individual interviews Constructivist grounded theory	31 PWID recruited through drug treatment services, homeless hostels, and day centres	Use of acidifiers	Rhodes' risk environment	Excessive acidifier use in drug preparation for injection is common and contributes to venous damage and risk for bacterial infections. Some participants determined the amount of acidifier to use through expert practice (e.g., visual cue of solution

			across London, UK 29% women; mean age 43 years; housing status not reported			clarity) and others through external factors (e.g., using one whole packet of acid, even if that is excessive and causes pain and injury). Some participants decreased acidifier use over time, in response to new information or pain/injury. The authors infer a peed to revisit design
						and distribution of acidifiers within harm reduction programs.
Harris M 2020a ⁶¹	England	Individual interviews Constructivist grounded theory	36 PWID, recruited through specialist drug services, homeless hostels, and day centres across London, UK. 12% women; mean 46 years; 64% unstably housed in past 12 months.	Experiences of injecting-related injuries and infections	Everyday violence Structural violence Cultural safety	Engagement with the medical system (including for injecting-related infections) is a "last resort"; often participants delayed as long as possible to the point that they were critically ill. Participants avoided or delayed accessing medical care for their own protection, including because of experiences of discrimination and undertreated withdrawal and pain; one participant specifically worried of stigma against mothers who use drugs and associated risks of child apprehension. Participants described leaving hospital prematurely and self-treating wounds instead.
Harris M 2020b ⁵⁶	England	Mixed methods Individual interviews Constructivist grounded theory	32 PWID, recruited through specialist drug services, homeless hostels, and day centres	Water for preparing injecting solutions	Rhodes' risk environment	Environmental constraints to sourcing sterile water for injection preparation (and staying hydrated to promote vein health) include lack of housing, public washrooms, or sterile water from harm reduction programs. When injecting in public places, fear of arrest

			across London, UK. 31% women; mean age 43 years; 94% had experienced homelessness			would lead people to rush their preparation and inject as fast as possible. As a result, participants described using more readily available but unsafe alternative water sources including puddle water, toilet cistern water, whisky, cola soda, and saliva to prepare injections, which were associated with bacterial infections. Participants described several strategies to promote health and safety despite these environmental constraints, including filtering water through alcohol swabs or asking passers-by for bottled water.
Jafari 2015 ⁷⁴	Canada	Mixed methods Individual interviews; direct observation and field notes Narrative analysis	8 PWID who were clients at a harm reduction- oriented medical respite program Gender, age, and current housing status not reported	Experiences of care for injecting- related infections	None specified	Participants described past experiences of leaving hospital before completion of their medical treatment because of judgmental and stigmatizing care. Clients with severe injecting-related infections who were being cared for at a harm reduction- oriented medical respite describe receiving less judgmental and stigmatizing care compared to their experience in acute care hospitals.
Krüsi 2009 ⁶⁵	Canada	Individual interviews Thematic analysis	22 PWID, recruited as clients at an HIV- focused residential and outpatient care facility in Vancouver	Use of a supervised injection site integrated within a community-based HIV care facility	Rhodes' risk environment	Participants accessing the supervised injection site found it a uniquely valuable setting to receive education on (and to implement) safer drug preparation and injecting techniques, which they attributed to reduced frequency of abscesses. When they did not have access to the supervised

			32% women; mean 44 years; housing status not reported			injecting facility, participants described rushing their drug preparation and injection out of fear, including not using water to dissolve their heroin sufficiently.
Mars 2016 ⁵⁷	USA	Ethnography and individual interviews Grounded theory	41 PWID recruited during ethnographic insertion in drug using community and with snowball sampling in Philadelphia (n=22) and San Francisco (n=19) 49% women; age unknown; homelessness "common".	Comparing perspectives of PWID in two different heroin markets.	Rhodes' risk environment	In San Franciso, where heroin was mostly in "tar" form, participants attributed abscesses to the characteristics of tar heroin including poor solubility. In Philadelphia, where more-soluble power heroin as well as cocaine was widely available, participants attributed abscesses to missing veins (i.e., injecting subcutaneously or intramuscularly) and when injecting cocaine. The authors attribute regional differences in abscess risk to geopolitical forces that have segmented the U.S. heroin market.
McNeil 2014 ⁶⁷	Canada	Individual interviews Thematic analysis	30 PWID who had experienced hospital discharge against medical advice within the prior two years, recruited from within a prospective cohort study in Vancouver 43% women; mean 45 years;	Hospital care experiences	Rhodes' risk environment Social violence	Participants left hospital prematurely (before the completion of their recommended treatment) because of inadequate pain and withdrawal management, and because of discriminatory, stigmatizing, and racist care experiences. These were influenced by hospital policies, written and unwritten.

			27% staying in emergency shelters or unhoused			
Meyer 2020 ⁷³	Kyrgyzstan	Individual interviews Content analysis	11 PWID who were incarcerated and injected diphenhydramine 10% women; average age not reported; all currently incarcerated	Diphenhydramine injecting in Kyrgyz prisons	Rhodes' risk environment	Participants attributed severe skin infections to injecting diphenhydramine while incarcerated, particularly in comparison to injecting heroin. Infectious risks associated with diphenhydramine were influenced by the denial of access to the prison's needle and syringe program to people taking methadone (which was common among people injecting diphenhydramine) and stigmatization and punishment of diphenhydramine users in the prison (which led people to delay seeking care for skin infections).
Paquette 2018 ⁶⁸	USA	Individual interviews "Mixed inductive and deductive approach"	46 PWID who attended syringe service programs or health services in Fresno, California (n=22) or community services agencies or street-based recruitment in Kern, California (n=24) 37% women; mean 39 years;	Stigmatizing health care experiences	Rhodes' risk environment	Participants described delaying or avoiding medical care ("until it was absolutely necessary") for injecting- related infections because of previous stigmatizing experiences. Instead, some people treat their own infections. Participants in rural areas also described feeling as if they could not attend their local harm reduction program for sterile injecting equipment as this would "out" them as a drug user to the small community.

			housing status not reported			
Phillips 2013 ⁵⁴	USA	Mixed methods Focus group interviews Qualitative analysis approach not specified	32 PWID recruited through street outreach in Denver, Colorado 50% women; mean age 50 years; housing status not reported	Perspectives on injecting-related bacterial infections, to inform development of a behaviour change intervention	Information- Motivation- Behavioral Skills model	 Most participants had experienced injecting-related bacterial infections. PWID attributed increased risk of infections to poor quality (or adulterated or contaminated) unregulated drugs, including tar heroin (compared to powder heroin or pharmaceutical opioid tablets); to injecting intramuscularly or subcutaneously; to reusing needles; and to not cleaning skin. Barriers to practicing safer drug preparation and injecting included lack of access to sterile equipment (influenced by a "paraphernalia law" that prohibited carrying a hypodermic needle without "proof of medical need"). Participants described delaying or avoiding medical care for infections due to negative health care experiences.
Pollini 2010 ⁷⁶	Mexico	Mixed methods Focus groups Grounded theory	47 PWID invited from among participants in a cohort study that used respondent- driven sampling 14% women; age not reported;	Barriers to sterile syringe access, including purchase from pharmacies	Rhodes' risk environment	Participants described many challenges in accessing sterile needles and syringes via purchasing at local pharmacies, including discrimination from pharmacists and pharmacists disclosing fear of "trouble with police" (despite syringe sales being legal). This led to syringe reuse being common practice. Participants did not spontaneously attribute risks for

			housing status not reported			abscesses to needle and syringe reuse, until asked by a focus group facilitator.
Pollini 2021 ⁶²	USA	Individual interviews Thematic analysis	20 PWID recruited through provider referral, street-based recruitment and snowball sampling 45% women; median age 26; housing status not reported	Scarcity of sterile needles and syringes in a rural environment	Rhodes' risk environment	 Scarcity of sterile needle and syringes led PWID to share and re-use syringes. Factors limiting sterile syringe access included pharmacies refusing to sell them or requiring an ID, and a state "drug paraphernalia" law that criminalizes possession of syringes. Participants would travel out-of-state to pharmacies that would sell syringes, but police were aware of this and would stop and search cars with out-of-state license plates after visiting a pharmacy. One participant obtained sterile syringes from a family member with diabetes and distributed them to people in her community who inject drugs.
Sheard 2008 ⁷⁷	England	Individual interviews Grounded theory	45 women who inject drugs recruited among clients of needle and syringe programs and addiction treatment programs in semirural North Nottinghamshire and urban Leeds, and through snowball sampling of	Assistance with injecting among women.	None specified	All participants (100% women) were injected by others, sometimes by a male partner who exerted power and control. Some participants shared needles and injecting equipment with partners as an intimate practice. Participants attributed injecting- related bacterial infections to unintentional subcutaneous injecting when self-injecting, caused by inexperience and a lack of knowledge about how to inject safely. Self- injecting was a positive experience for some women as it promoted independence; for others, it caused

-						
			participant			harm visible scars which worsened
			contacts.			social marginalization. Most
						participants accessed a local needle
			100% women;			exchange and had ample supply of
			age rage 16 – 46			sterile drug preparation and injecting
			years.			equipment. Cleanliness and hygiene
						were commonly raised as important
						reasons to avoid reusing or sharing of
						equipment.
Small	Canada	Individual interviews	50 PWID who use	Impact of the	None specified,	Participants described delaying or
2008 ⁶⁶			supervised	supervised	but motivated by	avoiding medical care because of
		Thematic analysis	injection sites in	consumption site	exploration of	previous negative experiences. By
			Vancouver.	on access to care	"social and	providing nonjudgmental care within a
				for injecting-	structural barriers	setting where drug use is
			42% women;	related bacterial	to care commonly	accommodated, contact with nurses
			median age 38;	infections.	experienced by	at a supervised injection site
			housing status		[injection drug	facilitated access to care for injecting-
			not reported		users]"	related infections.
Summers	USA	Mixed methods	12 PWID	Prevention and	Rhodes' risk	Participants described delaying,
2018 ⁷²			recruited from	treatment of skin	environment	avoiding, or prematurely leaving
		Individual interviews	needle and	infections		medical care for injecting-related skin
			syringe programs	incetions	Health Belief	and soft-tissue infections because of
		Thomas' general	in Boston,		Model (HBM) of	experiences of unaddressed pain and
		inductive approach	Massachusetts		health-seeking	withdrawal symptoms, stigma.
			and Sacramento,		behaviours	
			California			
					Conceptual Model	
					of Medical Care	
					Avoidance	

856 FIGURE LEGENDS

- 857 Figure 1. Illustrative schematic of pathway model to conceptualize how the risk environment shapes
- 858 risk for injecting-related bacterial and fungal infections at different moments. Macro-environmental,
- 859 micro-environmental, and individual-level factors interplay to influence risk at each moment.
- 860
- 861 Figure 2. PRISMA flow diagram of included studies in systematic review and thematic synthesis of
- social and structural determinants of injection drug use-associated bacterial and fungal infections.
- 863
- 864 Figure 3. Schematic summary of analytic and descriptive themes on social and structural determinants
- 865 of injection drug use-associated bacterial and fungal infections.



Figure 1. Illustrative schematic of pathway model to conceptualize how the risk environment shapes risk for injecting-related bacterial and fungal infections at different moments. Macro-environmental, micro-environmental, and individual-level factors interplay to influence risk at each moment.



874 875

Figure 2. PRISMA flow diagram of included studies in systematic review and thematic synthesis of social and structural determinants of injection drug use-associated bacterial and fungal infections.

for thin perp	878 879						
older rint i	880						
nt ha prep	881		Analytic themes		Descriptive themes	Codes	
yrigl the	882						
e cop splay	883 884				1. Unregulated drug supply	Unregulated drug quality [5]; Variation in drug supply [2]	
2. Th to dis	885	+)			2. Unsafe spaces	Housing [6]: Policing practices [6]: supervised consumption sites [3]	
202 nse e .	886		1. Social production of risk				
er 4, a lice	887		through stigma, criminalization.		3. Health care policies and practices	Discrimination and stigma affecting access to health care [12]; untreated pain and withdrawal affecting access to care [6]; premature hospital discharge [5]; Insurance [3]	
xiv a al lic	888		mandated abstinence, or austerity				
o Roe	889		policies.				
posted nted me Interna	890 891				4. Harm reduction programs	Equipment [4]; Operations [3]; Pharmacy access [4]; Opioid agonist treatment after hospital [5]	
sion gra 4.0	892						
his ver ho has CC-BY	893 894		2. Practices of care among people		5. Mutual care	Assisted injecting [2]; non-medical wound care [2]; non-medical sources of antibiotics [2]; sharing sterile equipment for safety [1]; sharing used	
20;1 ≥r.a	895		Agency and individual-environment	onment		equipment as care [1]; education from peers [1]	
800 apur	896		interactions promoting health			Vain and skin care [E], coursing cafer alternatives [2], changing practices	
222 or/fu	897		within the risk environment.		6. Self-care	after infection [5]: practices to avoid discrimination [3]	
2.10.02. the auth e availat	898						
	899						
bis mad	900						
101, t is I	901	Figure 3	3. Schematic summary of analy	tic and	descriptive themes on socia	al and structural determinants of injection drug use-associated	
10.1	902	bacteria	al and fungal infections.				
prg/1	903						

877